Geriatric Recovery Using Inpatient and Post-hospitalization Supplementation (GRIPS)

A Phase I Randomized Clinical Trial of In-hospital and Post-hospital Whey Protein vs. Low Quality Protein vs. Isocaloric Placebo Supplementation to Improve Recovery From Hospitalization in Older Adults

The purpose of the study is to determine the feasibility of nutritional interventions designed to help older patients maintain physical function after being in the hospital. We will test the feasibility and effect of nutritional interventions with whey protein, collagen or placebo on functional recovery from hospitalization in community dwelling older adults.

Study Overview

Detailed Description

We will compare in a randomized parallel design double blind pilot phase I study the feasibility of whey protein vs. collagen vs. isocaloric placebo supplementation in older adults during an acute hospitalization for a medical condition, and the treatments' effect size on physical function after hospital discharge.

Study Type

Interventional

Enrollment (Estimated)

160

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Texas
      • Galveston, Texas, United States, 77550
        • Recruiting
        • UTMB Acute Care for Elders Unit
        • Principal Investigator:
          • Elena Volpi, MD, PhD
        • Contact:
      • Galveston, Texas, United States, 77555

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 65 years or older.
  • Admitted to UTMB hospital for any acute medical condition
  • English speaking

Exclusion Criteria:

  • Inability to consent
  • Bed or wheelchair bound prior to hospitalization
  • Estimated creatinine clearance 20 ml/min or less, or end stage renal disease not on dialysis
  • AST/ALT 2.5 times above the normal limit
  • Active cancer
  • Palliative care/Hospice
  • Estimated protein intake >1.2 g/kg/day during the previous 24 hours
  • Any other condition or event considered exclusionary by the PI and faculty physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Whey Protein
30 g of whey protein twice daily during hospitalization and for 30 days after discharge
30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
Active Comparator: Collagen Protein
30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
Placebo Comparator: Placebo
30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Function
Time Frame: Change from baseline to 30 days after discharge
Short Physical Performance Battery (SPPB) scale, 0-12 points. 0=disabled; 12=high performance
Change from baseline to 30 days after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Elena Volpi, MD, PhD, UTMB

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 19, 2019

Primary Completion (Estimated)

March 31, 2024

Study Completion (Estimated)

March 31, 2025

Study Registration Dates

First Submitted

April 4, 2019

First Submitted That Met QC Criteria

April 4, 2019

First Posted (Actual)

April 5, 2019

Study Record Updates

Last Update Posted (Actual)

July 27, 2023

Last Update Submitted That Met QC Criteria

July 25, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 18-0247

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No. This is a small Phase 1 feasibility pilot study. Risk of loss of confidentiality

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on Whey Protein

3
Subscribe